Franklin Genomic Advancements ETFHELX
Type
ETF
Peer group
US equity: Healthcare
Net assets
$21.4M
Expense ratio
0.50%
1-year return
+40.4%
3 years, a year
+10.8%
5 years, a year
-5.6%
12-month yield
0.32%
Holdings
61
What it aims to do.
Capital appreciation.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| GH Guardant Health Inc | 6.77% |
| NTRA Natera Inc | 6.65% |
| KRYS Krystal Biotech Inc | 5.32% |
| UTHR United Therapeutics Corporation | 4.64% |
| INSM Insmed Inc | 4.52% |
| BBIO Bridgebio Pharma Inc | 4.22% |
| LGND Ligand Pharmaceuticals Incorporated | 3.53% |
| JOBY AstraZeneca PLC | 3.40% |
| ADPT Adaptive Biotechnologies Corp | 3.12% |
| VRTX Vertex Pharmaceuticals Incorporated | 2.99% |
More on HELX.
- HELX overview
- HELX holdings
- HELX risk
- HELX costs
- HELX money in and out
- HELX share classes
- Compare HELX with other funds
Returns after fees, from the fund's SEC filings up to Aug 2026. Past returns are not a promise. Not financial advice.